Abstract

Background

Amyotrophic lateral sclerosis is a chronic neurodegenerative disease characterized by progressive paralysis due to degeneration of motor neurons by unknown causes. Recent evidence shows that Wnt signaling is involved in neurodegenerative processes, including Amyotrophic Lateral Sclerosis. However, to date, little is known regarding the expression of Wnt signaling components in this fatal condition. In the present study we used transgenic SOD1G93A mice to evaluate the expression of several Wnt signaling components, with special focus on Frizzled-5 cellular expression alteration along disease progression.

Findings

Based on previous studies demonstrating the expression of Wnts and their transcriptional regulation during Amyotrophic lateral sclerosis development, we have analyzed the mRNA expression of several Wnt signaling components in the spinal cord of SOD1G93A transgenic mice at different stages of the disease by using real time quantitative PCR analysis. Strikingly, one of the molecules that seemed not to be altered at mRNA level, Frizzled-5, showed a clear up-regulation at late stages in neurons, as evidenced by immunofluorescence assays. Moreover, increased Frizzled-5 appears to correlate with a decrease in NeuN signal in these cells, suggesting a correlation between neuronal affection and the increased expression of this receptor.

Conclusions

Our data suggest the involvement of Wnt signaling pathways in the pathophysiology of Amyotrophic Lateral Sclerosis and, more specifically, the implication of Frizzled-5 receptor in the response of neuronal cells against neurodegeneration. Nevertheless, further
Experimental studies are needed to shed light on the specific role of Frizzled-5 and the emerging but increasing Wnt family of proteins research field as a potential target for this neuropathy.

**Introduction**

Amyotrophic lateral sclerosis (ALS) is the most common and fatal form of motor neuron (MN) degenerative disease, with an annual incidence of 1–3 cases per 100,000 inhabitants [1]. The development of the pathology is characterized by progressive MN degeneration in the brain and spinal cord, leading to a deterioration of the neuromuscular function and as result weakness, atrophy, paralysis of skeletal muscles and eventually death from respiratory failure within 3 to 5 years from diagnosis [2–6]. The etiology of the disease is unknown in most ALS cases, which are described as sporadic (SALS), whereas a 10–20% of ALS cases are classified as familial (FALS) [1–5]. The first gene to be identified as being mutated in ALS was the cytosolic copper/zinc superoxide dismutase (Cu/Zn SOD, SOD1) [7, 8] and to date, over 150 different mutations in SOD1 have been discovered (http://alsod.iop.kcl.ac.uk/). Interestingly, both SALS and FALS are suggested to have common pathological hallmarks [4, 9]. The SOD1<sup>G93A</sup> transgenic mouse is a valuable tool for ALS research, characterized by over-expression of the mutant human SOD1 and the development of an age-dependent degeneration of MNs, very similar to human ALS in terms of clinical and pathological features, including leading to progressive paralysis and death [10]. MN death seems to be driven by a convergence of damaging mechanisms, including glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, defects in RNA processing, neurofilament accumulation, growth factor abnormalities, astrogial and/or microglia dysfunction, defects in axonal transport, metabolic alterations, accumulation of protein aggregates and immune imbalance [3, 6, 9, 11]. However, the exact cellular and molecular mechanisms responsible for MN degeneration in ALS are not completely understood, and to date, there is no cure for this neuropathy.

The Wnt family of proteins plays key roles during central nervous system (CNS) development and adult tissue homeostasis by regulating different cellular processes, such as migration, proliferation, differentiation, polarisation, axonal guidance, cell-cell adhesion and synapse physiology [12–16]. Furthermore, Wnt signaling has been involved in several neuropathologies during adulthood, including Alzheimer [17, 18], Parkinson [19] and Huntington [20] diseases, spinal cord injury (SCI) [21–26] and ALS [27–33]. Briefly, Wnt proteins can modulate, at least, three different signaling pathways. On one hand, in the canonical/β-catenin pathway, Wnt ligands interact with one of the 10 Frizzled (Fz) receptors and a low-density Lipoprotein Receptor-related Protein 5/6 (LRP5/6) co-receptor, leading to active β-catenin translocation to the nucleus and gene expression induction by the interaction with T-cell Factor/Lymphoid Enhancer Factor (TCF/LEF) family of DNA-binding proteins [34–38]. On the other hand, the non-canonical Wnt/Ca²⁺ and PCP pathways are activated by Fz receptors without LRP involvement, or by different non-conventional receptors, such as Ryk and Receptor Tyrosine Kinase-Like Orphan Receptor (ROR-1/2) [37, 39–41]. Moreover, there are different regulatory mechanisms for the Wnt-mediated signaling, including different extracellular antagonists, such as secreted Frizzled-Related Proteins (sFRPs), Dickkopf (Dkk) or Wnt inhibitory factor 1 (Wif-1) [42, 43].

Interestingly, recent results demonstrate the expression of different Wnt signaling components in the spinal cord of ALS transgenic mice, with variations in several gene expression levels during the progression of the disease [27–33]. To gain further understanding of
involvement of Wnt mediated pathways in the pathogenesis of ALS, we analyzed the expression of several Wnt signaling components in the spinal cord of ALS transgenic mice at different stages by quantitative RT-PCR (RT-qPCR) and immunohistochemistry. Then, we determined the cellular expression pattern of Fz5 and its cellular protein expression changes at different stages of the pathology. Further experimental studies must be performed to determine the molecular mechanisms underlying the changes found and their role in the pathogenesis of ALS, which may lead to new strategies for treating neurodegenerative diseases through modulation of Wnt signaling pathways.

**Materials and Methods**

**Animals**

Experiments were performed in transgenic mice carrying the mutation G93A in SOD1 gene and in nontransgenic Wild-Type (WT) littermates as controls. Transgenic mice with the G93A human SOD1 mutation (B6SJL-Tg[SOD1-G93A]1Gur) were obtained from the Jackson Laboratory (Bar Harbor, ME), bred at the animal facilities of the Universidad de Zaragoza (Spain) and maintained at the Universitat Autònoma de Barcelona (Spain). Hemizygote B6SJL SOD1G93A males were obtained by crossing with B6SJL females from the CBATEG (Barcelona, Spain). The offspring was identified by PCR amplification of DNA extracted from the tail tissue. Mice were kept in standard conditions of temperature (22 ± 2°C) and a 12:12 light:dark cycle with access to food and water ad libitum. All experimental procedures were approved by the Ethics Committee of the Universitat Autònoma de Barcelona. Studies were performed in 16 weeks old WT and 8, 12 and 16 weeks old SOD1G93A mice (n = 6 each), representing pre-symptomatic, clinical symptoms onset and end stage of the disease, respectively [44–48].

**RNA isolation and RT-qPCR analysis**

At each of the time points chosen for study, animals were terminally anesthetized with pentobarbital and perfused intracardially with heparinized saline to remove blood from the tissue. Lumbar spinal cords were harvested and the anterior horns were gently dissected under a microscope. Total mRNA was isolated by using the RNeasy Mini Kit (Qiagen). Complementary DNA (cDNA) synthesis from DNase-treated RNA (0.5 μg) and the relative quantifications were performed as previously described [23] using 50 ng of cDNA and specific primers validated previously [26]. β-actin (forward 5’-AAGTCCCTACCCTCCAAAAG-3’, reverse 5’-AAGCAATGCTGTCACCTTC-3’. GenBank accession number NM_007393.3) was quantified in a separate well as real-time reporter.

**Immunohistochemistry**

Similarly, three WT, and 8w, 12w and 16w old SOD1G93A mice were intracardially perfused with heparinized saline solution followed by 4% paraformaldehyde. The lumbar spinal cords were harvested and then post-fixed for 4h in 4% paraformaldehyde, cryoprotected by immersion in 30% sucrose for 48h, embedded in OCT frozen medium (Sakura). Ten series of 40μm transverse sections were cut using a cryotome (Leica) and collected serially in Olmos solution.

The cellular protein expression and localization of Fz1, Fz4 and Fz5 in both WT and transgenic mice spinal cord was performed by immunofluorescence assays following the same protocol detailed in a previous report [23]. The following primary antibodies produced in rabbit and obtained from Abcam were used: anti-Fz1 (1:50; ab71342), anti-Fz4 (1:5000; ab83042) and anti-Fz5 (1:100; ab75234), followed by the corresponding Dylight594 (1:500; Abcam, ab96897)
anti-rabbit. All sections used were processed at the same time and following the same experimental protocol.

To determine the cellular Fz5 expression pattern, double immunofluorescence was performed by combining Fz5 staining with specific astrocytic (glial fibrillary acidic protein; GFAP), neuronal (neuronal nuclei; NeuN) and MN (choline acetyltransferase; ChAT) markers, and also with the mitochondrial SOD2 staining in MNs. The sections were processed as detailed above for Fz5 detection, and the following primary antibodies were used for the different cell types: mouse anti-GFAP (1:1000; Sigma, G3893), mouse anti-NeuN (1:250; Millipore, MAB377), mouse anti-SOD2 (1:100; Abcam, ab110300) and goat anti-ChAT (1:100; Millipore, AB144P). Subsequently, the corresponding Dylight488-linked anti-mouse (1:500; Abcam, ab96879) or Alexa488-linked anti-goat (1:1000; Life technologies, A11055) secondary antibody was used.

Finally, sections were analyzed using both the BX61 Motorized Research Microscope (Olympus) and a Leica TCS SP5 resonant scanner confocal microscope (Leica Microsystems). For single immunohistochemistry experiments, the sections processed without the primary antibody were used as controls. For double immunohistochemistry, in order to confirm lack of cross reactivity, sections were processed without the second primary antibody and used as controls. No non-specific staining was observed.

**TUNEL Assay**

Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was performed to identify cells undergoing apoptosis. Using the In Situ Cell Death Detection Kit, TMR red from Roche (no. 12156792910), spinal cord sections were treated according to manufacturer’s instructions. For dual immunofluorescence, spinal cord sections were then exposed to Fz5 antibody as described above. As negative control, we omitted the TdT enzyme in the labeling reaction mixture, and, as a positive control, we pretreated sections with DNase I and induced TUNEL positivity in all cells.

**Statistical analysis**

All values are expressed as the mean ± SEM. Statistical comparisons were performed using one-way ANOVA, followed by Tukey’s post-hoc test to determine the individual differences between the means. In all cases, p < 0.05 was considered to be statistically significant. All statistical analyses were performed using GraphPad Prism (version 6.01).

**Results**

The Wnt family mRNA expression is modulated by the progression of the ALS pathology

Based on previous findings on Wnt family expression in ALS [27–33], we first assessed the mRNA profile of a set of Wnt family members with reported changes of expression associated to the disease progression. We evaluated the mRNA expression of Wnt2, -4, -5a and -7b ligands; Fz1, -2, -3, -4, -5, -8, Ror2 and Ryk receptors; and the Wif1 secreted inhibitor in both WT and ALS transgenic mice. Between 8w and 12w, most of the molecules analyzed did not show significant changes in their expression levels, and only Wnt4 and Fz4 were significantly down-regulated at 12w (Fig 1). In contrast, the majority of significant changes were observed at the later stage of the pathology, at 16w. The mRNA expression of Wnt5a, Wnt7b, Fz1, Fz2, Fz3, Fz8, Ror2 and Wif1 was significantly up-regulated when compared to the levels detected...
in WT mice. Moreover, the mRNA expression of Fz4 was significantly down-regulated at this time point (Fig 1).

**Fig 1.** Temporal mRNA expression pattern of different Wnt family members in the spinal cord of both WT and ALS transgenic mice. The temporal mRNA expression pattern of Fz1, Fz2, Fz3, Fz4, Fz5, Ror2, Ryk, Wif1, Wnt2, Wnt4, Wnt5a and Wnt7b was quantified using real time quantitative PCR using specific primers, both in the WT and ALS transgenic mice spinal cord and at different stages of the disease. Differences were calculated by setting the expression values of the WT samples at 1 and normalising against ribosomal 18S rRNA. In all cases, the data are presented as the mean ± SEM; * p < 0.05 versus WT.
Protein expression of Fz1, Fz4 and Fz5 receptors and increased immunoreactivity of Fz5 in the spinal cord of ALS transgenic mice

Next, using single immunohistochemistry, we investigated the protein expression of Fz1, Fz4 and Fz5, as representatives of an increase, a decrease and no change in mRNA expression levels. As previously reported by our group, Fz1 was expressed by neurons and oligodendrocytes while Fz4 was expressed by astrocytes [26] in the spinal cord of WT animals, a cell pattern and distribution that was unaltered in the transgenic mice. By contrast, Fz5 showed changes in its expression pattern during the progression of the disease (Fig 2), so the rest of experiments focused in this receptor. We found an increase in the immunoreactivity of Fz5 receptor in SOD1 mice spinal cord concomitant to disease progression, which seems to specifically affect neurons located in different layers of the spinal gray matter (Fig 3). Interestingly, this increase seemed to match with a decrease in NeuN immunoreactivity in these same cells (Fig 4). Indeed, Fz5 expression in the ventral horn of the spinal gray matter co-localized with the MN marker ChAT (Fig 5) of both WT and SOD1 transgenic mice at the different times analyzed. However, MNs were not among the cells with increased Fz5 immunoreactivity in the spinal cord of ALS transgenic mice.

Fz5 was also located in astrocytes of both WT and SOD1 transgenic mice, mainly in the regions in close contact with the pial surface. However, we did not observe variations in protein expression of Fz5 in astrocytes, since immunoreactivity levels of the receptor do not seem to be altered at any of the stages evaluated for this condition, in contrast with the remarkable increase of GFAP expression or glial reactivity observed at advanced stages of the disease (Fig 6).

Although loss of MNs is the main characteristic of ALS, there is no conclusive evidence that apoptosis is involved [49, 50]. We performed TUNEL staining to look for evidences of nuclear DNA breakdown and identify cells undergoing apoptosis. Nevertheless, no TUNEL-positive neurons were identified in the spinal cords of transgenic mice (data not shown) at the different times analyzed. Furthermore, based on the literature that describes an increase of the SOD2 mitochondrial enzyme associated with neurodegenerative processes [51], we performed double immunohistochemistry assays to evaluate if there was any correlation between increased expression of Fz5 and SOD2 in these same cells. As expected, we found an important increase in the expression of SOD2 in correlation with the progression of the disease, however, we did not observe a clear correlation regarding co-localization with Fz5 (Fig 7).

Discussion

ALS is the most common form of MN disease characterized by both upper (corticospinal/corticobulbar) and lower (spinal/bulbar) MN degeneration [11]. To date, the only available treatment for ALS is riluzole, an antiglutamatergic agent that blocks the presynaptic release of glutamate, but this treatment only slows down the progression of the disease and gives the patient few months of extended life span [52, 53]. However, the causes of the disease and the mechanisms causing premature death of MN are not clear. Interestingly, recent studies have provided experimental evidences suggesting the involvement of the Wnt family of proteins in the progression of some neuropathologies [17–26], including ALS [27–33]. In this study, we found that several Wnt signaling components were differentially expressed at mRNA level in the spinal cord of SOD1G93A mice at different stages of the disease. In agreement with previous studies in the literature, we have identified an increase in mRNA expression of most of these molecules at late stages. Only Wnt4 at 12w and Fz4 at 12–16w showed significant decreases in the expression of their mRNA. Noteworthy, these results do not exactly match a previous study...
but is important to point out that both time points for the different stages of the disease and the PCR technique (mice specific array for Wnt signaling pathway) differ from ours. When we investigated the protein expression of Fz1, Fz4 and Fz5 as representatives of the different mRNA expression patterns, we found that Fz1 and Fz4 showed no changes in protein expression during disease progression. Instead, Fz5 immunoreactivity begins to increase at 12w in some cells, and clearly observed at 16w. The analysis was performed in WT and ALS mice spinal cords at 8w, 12w and 16w. Scale bars = 200 μm.

Fig 2. Protein expression of Fz1, Fz4 and Fz5 receptors in the spinal cord of both WT and ALS transgenic mice. This figure shows representative images obtained from the microscopic evaluation of sections processed by simple immunofluorescence to visualize Fz2, Fz4 and Fz5. Fz1 and Fz4 receptors do not undergo changes in their cellular expression pattern during disease progression. Instead, Fz5 immunoreactivity begins to increase at 12w in some cells, and clearly observed at 16w. The analysis was performed in WT and ALS mice spinal cords at 8w, 12w and 16w. Scale bars = 200 μm.

doi:10.1371/journal.pone.0155867.g002
although there were also variations on their levels of mRNA expression. Interestingly, the expression of Fz1 has been recently associated to neural progenitor cells and immature neurons in adult mice brain [54]. By contrast, Fz5 receptor, whose mRNA expression was not modified throughout symptoms progression, showed a clear alteration in its protein expression at cellular level. We found that Fz5 co-localized with MNs immunopositive for ChAT staining, and also with other neurons expressing the neuronal marker NeuN. Furthermore, from 12w and particularly at 16w, we observed a marked increase in the immunoreactivity of Fz5 in cells that co-express NeuN, and in others that appear to be losing the expression of this neuronal marker.

**Fig 3. Neuronal location of Fz5 receptor in the spinal cord of both WT and ALS transgenic mice.** This figure shows representative images obtained from the microscopic evaluation of sections processed by double immunohistochemistry to visualize Fz5 in neurons (NeuN). Fz5 was expressed in most of neurons at different spinal cord laminae in WT mice and also at different neuropathological stages of ALS transgenic mice. The analysis was performed in WT and ALS mice spinal cords at 8w, 12w and 16w. The squares in the images showing the entire spinal cord sections represent the areas where the corresponding higher magnification micrographs were obtained. Scale bars = 50 μm.

doi:10.1371/journal.pone.0155867.g003
Fig 4. Increased expression of Fz5 receptor matched with a decrease in NeuN immunoreactivity at 16w. This figure shows representative images obtained from the microscopic evaluation of sections processed by double immunohistochemistry to visualize Fz5 in neurons (NeuN). Cells with increased immunoreactivity for Fz5 showed low levels of NeuN staining.
In this regard, there is experimental evidence showing a decrease in NeuN immunoreactivity specifically in neurons that are undergoing a degenerative process [55–57]. Moreover, by using SOD2 immunoreactivity to label mitochondrial swelling [51], we investigated if those neurons showed this sign of damage, but we did not find a correlation in this sense. Neither was found these cells undergoing apoptosis since TUNEL assays failed to identify TUNEL-positive

**Fig 5. Fz5 receptor was localized in motoneurons.** This figure shows representative images obtained from the microscopic evaluation of sections processed by double immunohistochemistry to visualize Fz5 in MNs (Chat). Fz5 receptor was expressed by MNs immunopositive for Chat staining both WT and ALS transgenic mice. No changes were found regarding to any increase in Fz5 immunoreactivity associated with MNs. The analysis was performed in WT and ALS mice spinal cords at 8w, 12w and 16w. The squares in the images showing the entire spinal cord sections represent the areas where the corresponding higher magnification micrographs were obtained. Scale bars = 50 μm.

doi:10.1371/journal.pone.0155867.g005
neurons in the spinal cords of transgenic mice at the different times analyzed (data not shown). This observation is in agreement with other studies which also did not found evidence of apoptosis [58–61], despite the existence of conflicting data regarding the activation of apoptotic pathways responsible for MN degeneration in ALS [49, 61, 62]. Therefore, the significance of the clear increase in Fz5 immunoreactivity associated to ALS progression is currently unknown.

The expression of Fz5 has been related with neuron survival and function. In this regard, a recent study described the necessary expression and activity of Fz5 receptor for neuronal survival in the parafascicular nucleus of the thalamus under physiological conditions, suggesting a role of this receptor in neural cell survival [63]. Other studies have described the participation of this receptor in synaptic physiology, being localized at both pre- and post-synaptic sites [64],
Fig 7. Location of Fz5 receptor and the mitochondrial enzyme SOD2. This figure shows representative images obtained from the microscopic evaluation of sections processed by double immunohistochemistry to visualize Fz5 and mitochondrial enzyme SOD2. We did not observe a correlation between increased immunoreactivity of Fz5 and SOD2 in these neuronal cells,
and also in the establishment of neuronal morphogenesis and polarity in cultured hippocampal neurons [65]. Therefore, the observed increase in Fz5 immunoreactivity during the evolution of the pathology might be related with the survival and/or the synaptic maintenance of neuronal cells involved in the pathophysiology and the progression of the disease. In this regard, it is known that ALS involves degeneration of MNs, as mentioned above, but is also characterized by loss or changes in other types of neurons [66], and it has been described that abnormalities in the activity of interneurons that synapse onto MNs might lead to hyperexcitability and excitotoxicity, contributing to degeneration in ALS [51, 67, 68].

The pathophysiology of ALS also involves non-neuronal cells [11]. Accordingly, we have also investigated if there was any alteration in Fz5 immunoreactivity in astrocytes, since there are evidences in the literature showing the potential toxic role of astrocytes for MNs in ALS [1, 69–71]. We observed a clear up-regulation of GFAP concomitant with the evolution of the disease, but no changes in Fz5 immunoreactivity were detected. The expression of Fz5 seems to be restricted to those astrocytes located in close contact with the pial surface.

In summary, our findings match with other reports describing a differential expression of the Wnt signaling components in the spinal cord of SOD1<sup>G93A</sup> mice. In particular, this is the first report describing a disturbed Fz5 cellular distribution in good correlation with the progression of ALS, which might be indicative of a pathophysiological role in those neurons with increased levels of expression. Nevertheless, further studies are needed to characterize the individual role of this receptor in the spinal cord physiology and ALS pathophysiology, to eventually lead to the development of novel therapeutic strategies.

Acknowledgments
We thank Sandra Vazquez and Virginia Perez for their expert technical support.

Author Contributions
Conceived and designed the experiments: CGF RM XN FJR. Performed the experiments: CGF RM JV. Analyzed the data: CGF RM JV XN FJR. Contributed reagents/materials/analysis tools: CGF RM JV XN FJR. Wrote the paper: CGF RM JV XN FJR.

References
1. Valori CF, Brambilla L, Martorana F, Rossi D. The multifaceted role of glial cells in amyotrophic lateral sclerosis. Cell Mol Life Sci. 2014; 71(2):287–97. Epub 2013/08/06. doi:10.1007/s00018-013-1429-7 PMID: 23912896
2. Ajroud-Driss S, Siddique T. Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta. 2015; 1852(4):679–84. Epub 2014/09/07. doi: 10.1016/j.bbadis.2014.08.010 PMID: 25193032
3. Moloney EB, de Winter F, Verhaagen J. ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front Neurosci. 2014; 8:252. Epub 2014/09/02. doi: 10.3389/fnins.2014.00252 PMID: 25177267; PubMed Central PMCID: PMC4132373.
4. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009; 65 Suppl 1:S3–9. Epub 2009/02/05. doi: 10.1002/ana.21543 PMID: 19191304
5. McGoldrick P, Joyce PJ, Fisher EM, Greensmith L. Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2013; 1832(9):1421–36. Epub 2013/03/26. doi: 10.1016/j.bbadis.2013.03.012 PMID: 23524377
Wnts Expression in Amyotrophic Lateral Sclerosis

6. Garbuzova-Davis S, Rodrigues MC, Hernandez-Ontiveros DG, Louis MK, Willing AE, Borlongan CV, et al. Amyotrophic lateral sclerosis: a neurovascular disease. Brain Res. 2011; 1398:113–25. Epub 2011/06/03. doi: 10.1016/j.brainres.2011.04.049 PMID: 21632035

7. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362 (6415):59–62. Epub 1993/03/04. doi: 10.1038/362059a0 PMID: 8446170

8. Boilée S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006; 52(1):39–59. Epub 2006/10/04. doi: 10.1016/j.neuron.2006.09.018 PMID: 17015226

9. Brites D, Vaz AR. Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front Cell Neurosci. 2014; 8:117. Epub 2014/06/07. doi: 10.3389/fncel.2014.00117 PMID: 24904276

10. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science. 1994; 264 (5166):1772–5. Epub 1994/06/17 PMID: 8209258

11. Mancuso R, Navarro X. Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Prog Neurobiol. 2015. Epub 2015/08/09. doi: 10.1016/j.pneurobiol.2015.07.004 PMID: 26253783

12. Megason SG, McMahon AP. A mitogen gradient of dorsal midline Wnts organizes growth in the CNS. Development. 2002; 129(9):2087–98. Epub 2002/04/18 PMID: 11959819

13. Ille F, Sommer L. Wnt signaling: multiple functions in neural development. Cell Mol Life Sci. 2005; 62 (10):1100–8. Epub 2005/06/02. doi: 10.1007/s00018-005-4552-2 PMID: 15928805

14. Curtinga G, Smith GM. Molecular/genetic manipulation of extrinsic axon guidance factors for CNS repair and regeneration. Exp Neurol. 2008; 209(2):333–42. Epub 2007/08/21. doi: 10.1016/j.expneurol.2007.06.026 PMID: 17706643

15. Ciani L, Salinas PC. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci. 2005; 6(5):351–62. Epub 2005/04/16. doi: 10.1038/nrn1665 PMID: 15832199

16. Inestrosa NC, Arenas E. Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci. 2010; 11(2):77–86. Epub 2009/12/17. doi: 10.1038/nrn2755 PMID: 20010950

17. De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G, et al. Activation of Wnt signal-regulated kinase 5 promotes neuronal death in a mouse model of Huntington's disease. J Neurosci. 2002; 22(19):7555–63. Epub 2002/06/19. doi: 10.1523/JNEUROSCI.22-19-07555.2002 PMID: 12093107

18. Inestrosa NC, Toledo EM. The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease. Mol Neurodegener. 2008; 3:9. Epub 2008/07/26. doi: 10.1186/1750-1326-3-9 PMID: 18652670

19. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Cossetti C, et al. Reactive astrocytes and Wnt/Frizzled receptor signaling mediate axon growth inhibition and limits functional recovery after spinal cord injury. J Neurotrauma. 2009; 26(7):955–64. Epub 2009/05/29. doi: 10.1089/neu.2008.0776 PMID: 19473059

20. Liu Y, Wang X, Lu CC, Kerman R, Steward O, Xu XM, et al. Repulsive Wnt signaling inhibits axon regeneration after spinal cord injury. J Neurosci. 2008; 28(33):8376–82. Epub 2008/08/15. doi: 10.1523/JNEUROSCI.1399-08.2008 PMID: 18701700

21. Miyashita T, Koda M, Kitajo K, Yamazaki M, Takahashi K, Kikuchi A, et al. Wnt-Ryk signaling mediates axon growth inhibition and limits functional recovery after spinal cord injury. J Neurotrauma. 2009; 26(7):955–64. Epub 2009/05/29. doi: 10.1089/neu.2008.0776 PMID: 19473059

22. Fernandez-Martos CM, Gonzalez-Fernandez C, Gonzalez P, Maqueda A, Arenas E, Rodriguez FJ. Differential expression of Wnts after spinal cord contusion injury in adult rats. PLoS One. 2011; 6(11):e27000. Epub 2011/11/11. doi: 10.1371/journal.pone.0027000 PMID: 22073235

23. Gonzalez P, Fernandez-Martos CM, Gonzalez-Fernandez C, Arenas E, Rodriguez FJ. Spatio-temporal expression pattern of frizzled receptors after contusive spinal cord injury in adult rats. PLoS One. 2012; 7(12):e50793. Epub 2012/12/20. doi: 10.1371/journal.pone.0050793 PMID: 23251385

24. Gonzalez P, Fernandez-Martos CM, Rytty P, Rodriguez FJ. The Ryk Receptor Is Expressed in Glial and Fibronectin-Expressing Cells after Spinal Cord Injury. J Neurotrauma. 2013; 30(10):806–17. Epub 2013/01/17. doi: 10.1089/neu.2012.2613 PMID: 23320533

25. Gonzalez P, Fernandez-Martos CM, Arenas E, Rodriguez FJ. Wnts are expressed in the spinal cord of adult mice and are differentially induced after injury. J Neurotrauma. 2013; 31(6):565–81. Epub 2013/12/26. doi: 10.1089/neu.2013.3067 PMID: 24367909
28. Li X, Guan Y, Chen Y, Zhang C, Shi C, Zhou F, et al. Expression of Wnt5a and its receptor Fzd2 is changed in the spinal cord of adult amyotrophic lateral sclerosis transgenic mice. Int J Clin Exp Pathol. 2013; 6(7):1245–60. Epub 2013/07/05 PMID: 23826406

29. Yu L, Guan Y, Wu X, Chen Y, Liu Z, Du H, et al. Wnt Signaling is altered by spinal cord neuronal dysfunction in amyotrophic lateral sclerosis transgenic mice. Neurochem Res. 2013; 38(9):1904–13. Epub 2013/06/21. doi: 10.1007/s11064-013-1096-y PMID: 23784673

30. Tury A, Tolentino K, Zou Y. Altered expression of atypical PKC and Ryk in the spinal cord of a mouse model of amyotrophic lateral sclerosis. Dev Neurobiol. 2014; 74(8):393–50. Epub 2013/10/15. doi: 10.1002/dneu.22137 PMID: 24123880

31. Wang S, Guan Y, Chen Y, Li X, Zhang C, Yu L, et al. Role of Wnt1 and Fzd1 in the spinal cord pathogenesis of amyotrophic lateral sclerosis-transgenic mice. Biotechnol Lett. 2013; 35(8):1199–207. Epub 2013/04/05. doi: 10.1007/s10529-013-1199-1 PMID: 23553522

32. Chen Y, Guan Y, Zhang Z, Liu H, Wang S, Yu L, et al. Wnt signaling pathway is involved in the pathogenesis of amyotrophic lateral sclerosis in adult transgenic mice. Neuroplast Res. 2012; 34(4):390–9. Epub 2012/05/31. doi: 10.1179/1743132812Y.0000000027 PMID: 22643080

33. Chen Y, Guan Y, Liu H, Wu X, Yu L, Wang S, et al. Activation of the Wnt/beta-catenin signaling pathway is associated with glial proliferation in the adult spinal cord of ALS transgenic mice. Biochem Biophys Res Commun. 2012; 420(2):397–403. Epub 2012/03/20. doi: 10.1016/j.bbrc.2012.03.006 PMID: 22426476

34. Michaelidis TM, Lie DC. Wnt signaling and neural stem cells: caught in the Wnt web. Cell Tissue Res. 2013; 6(7):1245–50. Epub 2013/12/19. doi:10.1007/s10529-013-1199-1 PMID: 24348333

35. Montcouquiol M, Crenshaw EB 3rd, Kelley MW. Noncanonical Wnt signaling and neural polarity. Annu Rev Neurosci. 2010; 33(2):84–110. doi:10.1146/annurev.neuro.29.051605.112933 PMID: 16776590

36. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev. 2006; 16(1):51–56. doi:10.1016/j.gde.2005.12.007 PMID: 16377174

37. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009; 10(7):468–77. Epub 2009/06/19. doi: 10.1038/nrm2717 PMID: 19536106

38. Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci. 2008; 121(Pt 6):737–48. doi:10.1242/jcs.00623 PMID: 18032270

39. Chiu AY, Zhai P, Dal Canto MC, Peters TM, Kwon YW, Prattis SM, et al. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci. 1995; 6(4):349–62. Epub 1995/08/01. doi:10.1006/mcne.1995.1027 PMID: 8846004

40. Fradkin LG, Dura JM, Noordermeer JN. Ryks: new partners for Wnts in the developing and regenerating nervous system. Trends Neurosci. 2010; 33(2):84–92. Epub 2009/12/17. doi: 10.1016/j.tins.2009.11.005 PMID: 20004982

41. Minami Y, Oishi I, Endo M, Nishita M. Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. Dev Dyn. 2010; 239(1):1–15. Epub 2009/06/17. doi:10.1002/dvdy.21991 PMID: 19530173

42. Kawano Y, Kypri R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003; 116(Pt 13):2627–34. Epub 2003/05/31. doi: 10.1242/jcs.00623 PMID: 12777574

43. Bovoletta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci. 2008; 121(Pt 6):737–46. Epub 2008/03/07. doi: 10.1242/jcs.026096 PMID: 18322270

44. Chiu AY, Zhai P, Dal Canto MC, Peters TM, Kwon YW, Prattis SM, et al. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci. 1995; 6(4):349–62. Epub 1995/08/01. doi:10.1006/mcne.1995.1027 PMID: 8846004

45. Mancuso R, Olivan S, Osta R, Navarro X. Evolution of gait abnormalities in SOD1(G93A) transgenic mice. Brain Res. 2011; 1406:65–73. doi:10.1016/j.brainres.2011.06.033 PMID: 21733494

46. Mancuso R, Santos-Nogueira E, Osta R, Navarro X. Electrophysiological analysis of a murine model of motoneuron disease. Clin Neurophysiol. 2011; 122(8):1660–70. doi: 10.1016/j.clinph.2011.01.045 PMID: 21354365

47. Mancuso R, Olivan S, Manzera P, Pasten-Zamorano A, Manzano R, Casas C, et al. Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012; 13(3):302–10. doi: 10.3109/17482968.2012.662688 PMID: 22424126
50. Yamazaki M, Esumi E, Nakano I. Is motoneuronal cell death in amyotrophic lateral sclerosis apoptosis? Neuropathology. 2005; 25(4):381–7. Epub 2005/12/31 PMID: 16382789

51. Chang Q, Martin LJ. Glycinergic innervation of motoneurons is deficient in amyotrophic lateral sclerosis. Mol Neurobiol. 2005; 24619579

52. Tomik B, Adamek D, Pierzchalski P, Banares S, Duda A, Partyka D, et al. Does apoptosis occur in mice with ALS? Folia Neuropathol. 2005; 43(2):75–81. Epub 2005/07/14. PMID: 16033692

53. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. Curr Med Chem. 2010; 17(18):1942–199. Epub 2010/04/10. PMID: 20377511

54. Mardones MD, Andaur GA, Varas-Godoy M, Henriquez JF, Salech F, Behrens MI, et al. Frizzled-1 receptor regulates adult hippocampal neurogenesis. Mol Brain. 2016; 9(1):29. doi:10.1186/s13041-016-0209-3 PMID: 26980182

55. Davoli MA, Fourtonis J, Tam J, Xanthoudakis S, Robertson GS, et al. Immunohistochemical and biochemical assessment of caspase-3 activation and DNA fragmentation following transient focal ischemia in the rat. Neuroscience. 2002; 115(1):125–36. Epub 2002/10/29. PMID: 12401327

56. Xu GP, Dave KR, Vivero R, Schmidt-Kastner R, Perez-Pinzon MA. Improvement in neuronal survival in SOD1(G93A) ALS mice: a quantitative confocal analysis. Am J Pathol. 2009; 174(2):574–85. Epub 2009/01/01. doi: 10.2353/ajpath.2009.080557 PMID: 19116365

57. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994; 330(9):585–91. Epub 1994/03/03. doi: 10.1056/NEJM19940303300901 PMID: 8302340

58. Mancuso R, Osta R, Navarro X. Presymptomatic electrophysiological tests predict clinical onset and survival in SOD1(G93A) ALS mice. Muscle Nerve. 2014; 50(6):943–9. doi: 10.1002/mus.24237 PMID: 24619579

59. Sathasivam S, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis—what is the evidence? Lancet Neurol. 2005; 4(8):500–9. Epub 2005/07/22. doi: 10.1016/S1474-4422(05)70142-3 PMID: 16033692

60. Yamazaki M, Esumi E, Nakano I. Is motoneuronal cell death in amyotrophic lateral sclerosis apoptosis? Neuropathology. 2005; 25(4):381–7. Epub 2005/12/31 PMID: 16382789

61. Chang Q, Martin LJ. Glycinergic innervation of motoneurons is deficient in amyotrophic lateral sclerosis. Mol Neurobiol. 2005; 24619579

62. Slater PG, Ramirez VT, Gonzalez-Billault C, Varela-Nallar L, Inestrosa NC. Frizzled-5 receptor is involved in neuronal polarity and morphogenesis of hippocampal neurons. PLoS One. 2013; 8(10):e78892. doi:10.1371/journal.pone.0078892 PMID: 24205342

63. Stephens B, Guiloff RJ, Navarrete R, Newman P, Nikhar N, Lewis P. Widespread loss of neuronal populations in the spinal ventral horn in sporadic motor neuron disease. A morphometric study. J Neurol Sci. 2006; 244(1–2):41–52. Epub 2006/02/21. doi: 10.1016/j.jns.2005.12.003 PMID: 16487542

64. McGown A, McDearmid JR, Panagiotaki N, Tong H, Al Mashhadi S, Redhead N, et al. Early interneuron dysfunction in ALS: insights from a mutant sod1 zebrafish model. Ann Neurol. 2013; 73(2):246–58. Epub 2013/01/03. doi: 10.1002/ana.23780 PMID: 23281025
68. Jiang M, Schuster JE, Fu R, Siddique T, Heckman CJ. Progressive changes in synaptic inputs to motor neurons in adult sacral spinal cord of a mouse model of amyotrophic lateral sclerosis. J Neurosci. 2009; 29(48):15031–8. Epub 2009/12/04. doi: 10.1523/JNEUROSCI.0574-09.2009 PMID: 19955354

69. Vargas MR, Johnson JA. Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics. 2010; 7(4):471–81. Epub 2010/10/01. doi: 10.1016/j.nurt.2010.05.012 PMID: 20880509

70. Papadeas ST, Kraig SE, O’Banion C, Lepore AC, Maragakis NJ. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc Natl Acad Sci U S A. 2011; 108(43):17803–8. Epub 2011/10/05. doi: 10.1073/pnas.1103141108 PMID: 21969586

71. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007; 10(5):615–22. Epub 2007/04/17. doi: 10.1038/nn1876 PMID: 17435755